Valuation Paradox

Immunovant's (IMVT) recent trading has been mixed, with a short-term decline of 4.8% over the past week and 10.7% over the past month, but longer-term gains remain strong, with a 1-year total shareholder return of 140.6%. The stock's fair value is estimated at $48.07, suggesting it is currently undervalued by 22%. This valuation is based on long-term earnings forecasts and a high implied P/E. However, a simpler check of the P/B ratio shows it is trading at 10.5x, significantly above the wider US Biotechs group, and close to the P/B of 10.8x for similar companies. This suggests that investors are paying a sector premium, but not a clear outlier price. The question remains whether this leaves limited margin for error if trial news or funding plans wobble, or whether it reflects a pipeline that is still being underestimated.